NEW YORK, March 23 /PRNewswire/ -- Paratek Pharmaceuticals, Inc., a
private Boston-based pharmaceuticals company that is engaged in the
development of new anti-infective therapies against drug-resistant pathogens
and therapies for the treatment of serious inflammation-related diseases for
which there are few effective therapies, announced that its Chief Executive
Officer, Thomas J. Bigger, will present an overview of the Company's strategy
and update on its research programs at the Wells Fargo Securities Health Care
Fireside Chats in New York tomorrow. Details of the presentation follow:
Date: Wednesday, March 24th, 2004
Time: 1:45 p.m. (EST)
Location: St. Regis Hotel, East 55th Street at Fifth Avenue,
Speaker: Thomas J. Bigger, Chief Executive Officer
Presentation: "An Introduction to Paratek"
To hear the presentation live, log on to www.paratekpharm.com. Please log
on to the site at least 10 minutes prior to the start time to allow for any
software downloads that may be necessary. An archive of the presentation will
also be available on this site for 90 days following the event.
Paratek is engaged in the discovery and commercialization of new
therapeutics that treat serious and life-threatening diseases, with a
particular focus on the growing worldwide problem of antibiotic resistance.
Paratek's lead programs are advancing novel compounds related to the
tetracycline family that can circumvent or block bacterial resistance, as well
as drugs that can prevent infection by many gram-negative bacteria by
interfering with Multiple Adaptational Response (MAR) mechanisms in bacteria.
Out of these efforts, Paratek has discovered a new class of antibiotics, the
aminomethylcyclines (AMCs), which target the need for new and potent
antibacterials to overcome the problem of rapidly growing bacterial
resistance. The Company's lead antibiotic clinical candidate,
PTK 0796/BAY73-7388, the first product from this class, is being developed in
a collaborative partnership with Bayer HealthCare AG.
Paratek has also established an internal effort to leverage Paratek's
chemical library by exploiting the application of its novel tetracycline-based
compounds in selected anti-inflammatory and neurodegenerative conditions
outside of the infectious disease area. Paratek maintains one of the world's
most active tetracycline chemical synthesis efforts and has produced a diverse
collection of novel compounds evolved from the tetracycline family. Paratek
has begun to leverage this unique asset to identify a number of improved
non-antibacterial products in serious diseases where the utility of
tetracyclines has or is being clinically validated by others.
A copy of the Paratek presentation will be available upon request.
For more information, visit Paratek's website at www.paratekpharm.com.
SOURCE Paratek Pharmaceuticals, Inc.